Isomorphic Labs
Alphabet's AlphaFold-derived drug design company; its first AI-designed oncology candidate was cleared for human trials in January 2026 after a $2.1B raise.
Co-developer of AlphaFold 3 with Google DeepMind and builder of the IsoDDE design engine. Raised about $2.1B (2025-26). ISM8969 cleared by FDA for first-in-human study on 28 January 2026; initial pipeline is oncology and immunology. Partnerships with Eli Lilly and Novartis.
Pages like this
not linked directly; found by shared links- CompanyGenerate:Biomedicines
Shares AI-designed proteins that grip the floppy parts of cancer drivers, De novo designed protein binders, AI-driven drug & target discovery, The valley of death between lab and product and the tag frontier.
- TechnologyADC payload neutralisers
Shares De novo designed protein binders, AI-driven drug & target discovery and the tag frontier.
- CompanyOrna Therapeutics (Eli Lilly)
Shares Eli Lilly (incl. Loxo) and the tag frontier.
- TechnologySystematic drug repurposing
Shares AI-driven drug & target discovery and the tag frontier.
- Key paperAlphaFold 2: predicting protein structures to near-experimental accuracy
Shares AlphaFold 3, De novo designed protein binders, AI-driven drug & target discovery, The valley of death between lab and product.
- TechnologyMolecular glue discovery platforms
Shares AI-driven drug & target discovery and the tag frontier.
- CompanyInsilico Medicine
Shares De novo designed protein binders, AI-driven drug & target discovery, The valley of death between lab and product.
- InstitutionCancer Center at Illinois
Shares AI-driven drug & target discovery, The valley of death between lab and product.